TABLE 4

Outcomes for complete versus noncomplete responders after 1 year of treatment with anti-interleukin-5 biologics

	Complete responders	Noncomplete responders	*Δ complete versus* Δ noncomplete responders p-value**
Clinical outcomes
Exacerbations in previous 12 months, n			0.008
At baseline	2.80±2.61	3.43±3.61
At 12 months	0	1.48±1.71
p-value	<0.0001	<0.0001
mOCS			<0.0001
At baseline	53 (18)	134 (63)
At 12 months	0	123 (58)
p-value	<0.0001	0.0009
Budesonide-equivalent dose, µg			0.0006
At baseline	1600 (1200–1600)	1600 (1600–2000)
At 12 months	1600 (800–1600)	1600 (1600–2000)
p-value	0.002	0.17
FEV₁, L			<0.0001
At baseline	2.26±0.85	2.18±0.83
At 12 months	2.47±0.87	2.21±0.85
Δ from baseline	0.21	0.03
p-value	<0.0001	0.63
FEV₁, % pred			<0.0001
At baseline	70±21	68±21
At 12 months	76±20	70±22
Δ from baseline	6	2
p-value	<0.0001	0.20
FEV₁/FVC			0.014
At baseline	0.64±0.13	0.65±0.13
At 12 months	0.67±0.10	0.65±0.13
p-value	<0.0001	0.69
FEV₁ >80%			0.008
At baseline	31	31
At 12 months	44	31
p-value	<0.0001	1.00
ACQ score			0.016
At baseline	2.32±1.32	2.67±1.24
At 12 months	1.28±1.11	1.99±1.26
Δ from baseline	−1.04	−0.68
p-value	<0.0001	<0.0001
ACQ ≤1.5			<0.0001
At baseline	33	21
At 12 months	67	40
p-value	<0.0001	0.0006
Biomarkers
Blood eosinophils, ×10⁹ L⁻¹			<0.0001
At baseline	0.40 (0.18–0.65)	0.23 (0.1–0.54)
At 12 months	0.06 (0.02–0.10)	0.06 (0.02–0.10)
p-value	<0.0001	<0.0001
F_ENO, ppb			0.71
At baseline	32 (18–64)	32 (14–63)
At 12 months	29 (16–54)	30 (16–60)
p-value	0.04	0.14

Data are presented as mean±sd, n (%), % or median (interquartile range), unless otherwise stated. mOCS: maintenance oral corticosteroids; FEV₁: forced expiratory volume in 1 s; FVC: forced vital capacity; ACQ: Asthma Control Questionnaire; F_ENO: exhaled nitric oxide fraction.